Retatrutide 5mg/10mg/15mg/20mg/30mg

Retatrutide is an active compound released by Eli Lilly in June 2023. It is a triple (GLP-1/GIP/Gcg) agonist based on the GLP/GI dual receptor agonist Tirzepatide through a hybrid glucagon (GlucagonGcg) related structure, and is a drug for the treatment of obesity and type 2 diabetes. This active compound can activate receptor agonists in our body, which helps control blood sugar and weight loss management. Indications and Efficacy: ★ Obesity Treatment: In the Phase II clinical trial, patients in the highest dose group (12 mg) lost an average of 24.2% weight after 48 weeks, and some patients lost more than 30%. ★ Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD): Retatrutide can reduce liver fat content by 86%, and more than 85% of patients achieve regression of liver steatosis. ★ Type 2 Diabetes: Significantly reduce glycated hemoglobin (HbA1c) and improve blood sugar control. ★ Potential Cardiovascular Benefits: Animal studies have shown that it may indirectly protect cardiovascular health by improving blood pressure and heart function, but further clinical verification is needed.